Effects of myelotoxic agents on cytokine production in murine long-term bone marrow cultures

Stem Cells
S P HauserD A Lipschitz


In long-term bone marrow cultures we studied the effect of the addition of the myelotoxic agents methotrexate (MTX) and ceftazidime (CEF) on the kinetics of cytokine production in the supernatant (SN) and on mRNA expression in the adherent stromal layer. In response to a medium change, a prompt and significant increase in colony-stimulating activity (CSA) and interleukin 6 (IL-6) concentrations in the SN occurred, peaking 12 h later. Two macrophage colony-stimulating factors (M-CSF) mRNA of 23 kb and 4 kb were identified. In response to the medium change, the 4.0-kb transcript increased significantly six h later. The 2.3-kb transcript expression was stronger than the 4-kb mRNA but did not cycle with medium change. At medium change, IL-6 mRNA was only minimally expressed; then a prompt increase occurred, which peaked six h later. The addition of 500 mg/ml (=915 microM) CEF to the culture caused a dose-dependent suppression of CSA and IL-6 supernatant concentrations and IL-6 and M-CSF mRNA expression. By contrast, 1 microM MTX had minimal effect on cytokine concentrations in the SN following medium change. mRNA expression was, however, suppressed. These results provide insights into the possible mechanisms whereby cytokines lead ...Continue Reading


Jun 1, 1977·Journal of Cellular Physiology·T M DexterL G Lajtha
Jan 1, 1992·Current Topics in Microbiology and Immunology·P Roth, E R Stanley
May 1, 1992·Journal of Cellular Physiology·H E McGrathP J Quesenberry
Jan 1, 1990·Annual Review of Immunology·K Dorshkind
Jan 1, 1990·The Journal of Emergency Medicine·R Santiago, M C Rashkin
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M B LadnerE R Stanley
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J Van SnickR J Simpson
Feb 1, 1988·European Journal of Immunology·J Van SnickR J Simpson
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C P ChiuF Lee
Nov 1, 1987·Antimicrobial Agents and Chemotherapy·K A Neftel, U Hübscher
Jul 1, 1985·The Journal of Infectious Diseases·K A NeftelM R Müller
Oct 1, 1969·Journal of Cellular Physiology·R G WortonJ E Till
Jul 1, 1983·The Journal of Antimicrobial Chemotherapy·L J EronD M Poretz
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·G M Church, W Gilbert
Dec 17, 1983·British Medical Journal·B RouveixB Regnier
Jan 1, 1983·Journal of Cellular Physiology·R K ShadduckT M Dexter
Jan 1, 1982·Journal of Cellular Physiology. Supplement·T M Dexter
Feb 2, 1995·The New England Journal of Medicine·S C Manolagas, R L Jilka
Apr 1, 1995·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·S P HauserD A Lipschitz
Apr 1, 1994·British Journal of Haematology·S P HauserD A Lipschitz
Dec 1, 1996·British Journal of Haematology·S P HauserD A Lipschitz

❮ Previous
Next ❯


Jul 24, 2008·The Annals of Pharmacotherapy·Craig B WhitmanLars O Sjoholm
Oct 29, 2005·Journal of Experimental Zoology. Part A, Comparative Experimental Biology·Tobias UllerJean Clobert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

British Journal of Haematology
S P HauserD A Lipschitz
International Journal of Antimicrobial Agents
M J Hicks, C M Flaitz
Journal of Accident & Emergency Medicine
M MastrantonioA Gammon
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
T M Weller, E N Rees
European Journal of Clinical Pharmacology
K M Rhodes, S N Brown
© 2021 Meta ULC. All rights reserved